The Food and Drug Administration approved expanded use of Vertex Pharmaceuticals' cystic fibrosis drug Orkambi.
The agency first approved Orkambi in 2015 for cystic fibrosis patients age 12 and older. Now, the drug can also be used to treat children ages 6 to 11.
Despite the approval, Boston-based Vertex lowered its 2016 sales forecast for the drug from about $1 billion to no more than $990 million.
More articles on supply chain:
US consumer confidence index at highest level in 9 years
Drug reviewers often ditch FDA for pharma industry, research finds
Why patient advocacy groups are silent about high drug prices